Voyxact, sibeprenlimab-szsi
Named-patient access overview. Voyxact is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Voyxact
Voyxact (sibeprenlimab-szsi) is manufactured by Otsuka and indicated for Proteinuria reduction in primary IgA nephropathy (IgAN) at risk of progression. It is an oral small molecule approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Voyxact
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Voyxact for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Voyxact is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Voyxact in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Voyxact
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.